World Health Organization Sounds Warning Over Critical Lack of Weight-Loss Jabs
Fewer than 10% of people that would benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it issues its inaugural guidance on the medications.
Given more than one billion people worldwide currently classified as obese, it is urging broader and more equitable availability to these injectable treatments.
Per estimates, over two billion are projected to be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be treated with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to universal availability to the jabs that can aid individuals in losing considerable body mass, explains the organization.
Skinny Jab Scarcity
Despite the current most optimistic case, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, per the WHO.
The guideline calls on nations and manufacturers to expand availability, by approaches like patent sharing.
A patent on a key compound – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and enhance the sense of being full so individuals reduce food intake.
Individuals typically begin shedding pounds within a few weeks of beginning the weekly injections.
Studies suggests users may see weight return a year later of discontinuing the drug, because their usual food cravings return.
To be overweight or obese increases your chance for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
